{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:37:33Z","timestamp":1773365853731,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12943-015-0363-8","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T18:00:33Z","timestamp":1429293633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing"],"prefix":"10.1186","volume":"14","author":[{"given":"Jana","family":"Linhartova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Hovorkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Jaruskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Klamova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Zuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machova Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"363_CR1","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135.","journal-title":"Leukemia"},{"key":"363_CR2","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X, Verma D, Quint\u00e1s-Cardama A, O'Brien S, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024\u20139.","journal-title":"Am J Hematol"},{"key":"363_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32:415\u201323.","journal-title":"J Clin Oncol"},{"key":"363_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515\u201322.","journal-title":"Blood"},{"key":"363_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424\u201330.","journal-title":"J Clin Oncol"},{"key":"363_CR6","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1111\/j.1751-553X.2010.01236.x","volume":"32","author":"PA Bartley","year":"2010","unstructured":"Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, et al. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Lab Hematol. 2010;32:e222\u2013228.","journal-title":"Int J Lab Hematol"},{"key":"363_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2353\/jmoldx.2009.080048","volume":"11","author":"AA Morley","year":"2009","unstructured":"Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, et al. Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia. J Mol Diagn. 2009;11:201\u201310.","journal-title":"J Mol Diagn"},{"key":"363_CR8","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","volume":"116","author":"M Sobrinho-Sim\u00f5es","year":"2010","unstructured":"Sobrinho-Sim\u00f5es M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010;116:1329\u201335.","journal-title":"Blood"},{"key":"363_CR9","first-page":"4146","volume":"5","author":"CF Waller","year":"1999","unstructured":"Waller CF, Dennebaum G, Feldmann C, Lange W. Long-template DNA polymerase chain reaction for the detection of the bcr\/abl translocation in patients with chronic myelogenous leukemia. Clin Cancer Res. 1999;5:4146\u201351.","journal-title":"Clin Cancer Res"},{"key":"363_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/gcc.21989","volume":"51","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M, et al. Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia. Genes Chromosomes Cancer. 2012;51:1045\u201353.","journal-title":"Genes Chromosomes Cancer"},{"key":"363_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719\u201324.","journal-title":"Leukemia"},{"key":"363_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/leu.2010.174","volume":"24","author":"J Score","year":"2010","unstructured":"Score J, Calasanz MJ, Ottman O, Pane F, Yeh RF, Sobrinho-Sim\u00f5es MA, et al. Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 2010;24:1742\u201350.","journal-title":"Leukemia"},{"key":"363_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.dnarep.2011.08.010","volume":"10","author":"T Burmeister","year":"2011","unstructured":"Burmeister T, Gr\u00f6ger D, K\u00fchn A, Hoelzer D, Thiel E, Reinhardt R. Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias. DNA Repair (Amst). 2011;10:1131\u20137.","journal-title":"DNA Repair (Amst)"},{"key":"363_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2353\/jmoldx.2009.080150","volume":"11","author":"E Mattarucchi","year":"2009","unstructured":"Mattarucchi E, Spinelli O, Rambaldi A, Pasquali F, Lo Curto F, Campiotti L, et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol Diagn. 2009;11:482\u20137.","journal-title":"J Mol Diagn"},{"key":"363_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.leukres.2012.10.007","volume":"37","author":"M Karl","year":"2013","unstructured":"Karl M, Krumbholz M, Tauer JT, Jacobs U, Metzler M, Suttorp M. Identification of the genomic BCR-ABL1 fusion sequence from blood specimen stored on filter paper. Leuk Res. 2013;37:117\u20139.","journal-title":"Leuk Res"},{"key":"363_CR16","doi-asserted-by":"crossref","unstructured":"Shibata Y, Malhotra A, Dutta A. Detection of DNA fusion junctions for BCR-ABL translocations by Anchored ChromPET. Genome Med. 2010; doi:10.1186\/gm191.","DOI":"10.1186\/gm191"},{"key":"363_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/leu.2008.386","volume":"23","author":"M Zaliova","year":"2009","unstructured":"Zaliova M, Fronkova E, Krejcikova K, Muzikova K, Mejstrikova E, Stary J, et al. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR\/ABL-positive ALL: implications for residual disease monitoring. Leukemia. 2009;23:944\u201351.","journal-title":"Leukemia"},{"key":"363_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/gcc.20796","volume":"49","author":"J Zuna","year":"2010","unstructured":"Zuna J, Zaliova M, Muzikova K, Meyer C, Lizcova L, Zemanova Z, et al. Acute leukemias with ETV6\/ABL1 (TEL\/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer. 2010;49:873\u201384.","journal-title":"Genes Chromosomes Cancer"},{"key":"363_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/sj.leu.2401256","volume":"13","author":"J Zuna","year":"1999","unstructured":"Zuna J, Hrusak O, Kalinova M, Muzikova K, Stary J, Trka J. TEL\/AML1 positivity in childhood ALL: average or better prognosis? Czech Paediatric Haematology Working Group. Leukemia. 1999;13:22\u20134.","journal-title":"Leukemia"},{"key":"363_CR20","doi-asserted-by":"publisher","first-page":"8347","DOI":"10.1158\/0008-5472.CAN-06-1966","volume":"66","author":"J Wang","year":"2006","unstructured":"Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2\/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347\u201351.","journal-title":"Cancer Res"},{"key":"363_CR21","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","volume":"68","author":"YL Choi","year":"2008","unstructured":"Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008;68:4971\u20136.","journal-title":"Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-015-0363-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0363-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-015-0363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:00:58Z","timestamp":1630580458000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-015-0363-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1186\/s12943-015-0363-8","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]},"assertion":[{"value":"22 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"89"}}